Published in Toxicol Appl Pharmacol on June 01, 1998
Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol (2009) 2.15
Allometric scaling of xenobiotic clearance: uncertainty versus universality. AAPS PharmSci (2001) 0.91
Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs. Xenobiotica (2011) 0.78
Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem (2005) 2.14
Evidence for natural horizontal transfer of tetQ between bacteria that normally colonize humans and bacteria that normally colonize livestock. Appl Environ Microbiol (1994) 1.75
Toxicokinetics of paraquat in humans. Hum Exp Toxicol (1990) 1.44
Isolation of markers for chondro-osteogenic differentiation using cDNA library subtraction. Molecular cloning and characterization of a gene belonging to a novel multigene family of integral membrane proteins. J Biol Chem (1996) 1.42
Prognostic value of plasma and urine paraquat concentration. Hum Toxicol (1987) 1.42
Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol (1997) 1.38
Retracted Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol (2000) 1.34
New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol (2000) 1.32
Quality of life following intensive care. J Gen Intern Med (1988) 1.27
Retracted Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem (2001) 1.26
The effect of knocking-down nucleostemin gene expression on the in vitro proliferation and in vivo tumorigenesis of HeLa cells. J Exp Clin Cancer Res (2004) 1.26
Prognosis and treatment of paraquat poisoning: a review of 28 cases. J Toxicol Clin Toxicol (1982) 1.25
Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol (1997) 1.16
Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol (2001) 1.15
Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol (1987) 1.15
Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab (2000) 1.15
Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J Neurosci Res (2000) 1.09
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost (2005) 1.06
Elimination of paraquat. Hum Toxicol (1987) 1.06
Telesurveillance of elderly patients by use of passive infra-red sensors in a 'smart' room. J Telemed Telecare (2003) 1.06
Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med (1995) 1.01
Logical memory subtest of the Wechsler Memory Scale: age and education norms and alternate-form reliability of two scoring systems. J Clin Exp Neuropsychol (1987) 1.00
Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs (2001) 0.99
Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther (1993) 0.99
Central nervous system involvement in Sjögren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT. Ann Med Interne (Paris) (1999) 0.98
Role of P-170 glycoprotein in colchicine brain uptake. J Neurosci Res (1997) 0.98
Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br J Pharmacol (1999) 0.97
Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther (2001) 0.97
Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg (1987) 0.96
Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology (1994) 0.94
Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J Pharmacol Exp Ther (1997) 0.93
Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol (1994) 0.93
Pharmacokinetics of colchicine: a review of experimental and clinical data. Z Gastroenterol (1992) 0.93
Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther (1990) 0.92
Effect of viscoelastic properties of resilient denture liners on pressures under dentures. J Oral Rehabil (2001) 0.91
Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem (1996) 0.91
Modulation of P-glycoprotein activity by glial factors and retinoic acid in an immortalized rat brain microvessel endothelial cell line. Neurosci Lett (1997) 0.90
Autotransplantation of heart for repair of left ventricular rupture after mitral valve replacement. Transplant Proc (2001) 0.89
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression. Antimicrob Agents Chemother (2013) 0.89
Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol (2004) 0.87
Identification of a novel frame-shift mutation in PRSS1 gene in Han patients with autoimmune pancreatitis. Curr Mol Med (2014) 0.87
Absorption and elimination of viper venom after antivenom administration. J Pharmacol Exp Ther (1998) 0.87
Vector-mediated drug delivery to the brain. Expert Opin Biol Ther (2001) 0.85
Enhanced cellular uptake and transport of polyclonal immunoglobulin G and fab after their cationization. J Drug Target (2000) 0.85
Morphine pharmacokinetics in renal failure. Anesthesiology (1987) 0.85
Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. Drug Metab Dispos (1998) 0.85
Changes in the execution of a complex manual task after ipsilateral ischemic cerebral hemispheric stroke. Arch Phys Med Rehabil (1996) 0.85
Colchicine-specific Fab fragments alter colchicine disposition in rabbits. J Pharmacol Exp Ther (1992) 0.84
A novel recycle batch immobilized cell bioreactor for propionate production from whey lactose. Biotechnol Bioeng (1995) 0.83
Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. Fundam Clin Pharmacol (1989) 0.83
An autocrine system for C-type natriuretic peptide within rat carotid neointima during arterial repair. Am J Physiol (1997) 0.83
Cardiac glycosides. 6. Gitoxigenin C16 acetates, formates, methoxycarbonates, and digitoxosides. Synthesis and Na+,K+-ATPase inhibitory activities. J Med Chem (1986) 0.83
Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Hum Exp Toxicol (1996) 0.83
[Alkaloids of Colubrina faralaotra ssp. faralaotra (author's transl)]. Planta Med (1975) 0.83
Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. Pharm Res (2001) 0.83
Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol (1996) 0.82
Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. Hum Exp Toxicol (1992) 0.82
Effects of mode of inhalation of carbon monoxide and of normobaric oxygen administration on carbon monoxide elimination from the blood. Hum Exp Toxicol (1996) 0.82
Stereoselectivity of antibodies for the bioanalysis of chiral drugs. Pharm Res (1997) 0.82
Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits. J Pharmacol Exp Ther (1994) 0.82
Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. Scand J Gastroenterol (1994) 0.81
Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. J Pharm Sci (1999) 0.81
Snake F(ab')2 antivenom from hyperimmunized horse: pharmacokinetics following intravenous and intramuscular administrations in rabbits. Pharm Res (1995) 0.81
Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab. Toxicol Appl Pharmacol (1996) 0.80
High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life. Clin Pharmacol Ther (2008) 0.80
Nutritional (n-3) polyunsaturated fatty acids influence the behavioral responses to positive events in mice. Neurosci Lett (2000) 0.80
Morphine-induced sensitization of locomotor activity in mice: effect of social isolation on plasma corticosterone levels. Brain Res (2000) 0.80
Colchicine concentration in leukocytes of patients with familial Mediterranean fever. Br J Clin Pharmacol (1994) 0.80
Monoclonal digoxin-specific antibodies induce dose- and affinity-dependent plasma digoxin redistribution in rats. Pharm Res (1995) 0.80
Colonic ischemia reveals thromboangiitis obliterans (Buerger's disease). Gastroenterology (1996) 0.80
Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol (1994) 0.80
Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci (1997) 0.80
A critical review of antidotal immunotherapy for low molecular weight toxins. Current antidotes and perspectives. Arch Toxicol Suppl (1997) 0.80
Effect of dietary alpha-linolenic acid on functional characteristic of Na+/K(+)-ATPase isoenzymes in whole brain membranes of weaned rats. Biochim Biophys Acta (1993) 0.80
Diet deficient in alpha-linolenic acid alters fatty acid composition and enzymatic properties of Na+, K+-ATPase isoenzymes of brain membranes in the adult rat. J Nutr Biochem (1999) 0.80
Protein phosphatase 2A: identification in Oryza sativa of the gene encoding the regulatory A subunit. Plant Mol Biol (2001) 0.79
Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions. Toxicol Appl Pharmacol (1996) 0.79
Effect of social isolation on the metabolism of morphine and its passage through the blood-brain barrier and on consumption of sucrose solutions. Psychopharmacology (Berl) (1999) 0.79
Effect of fish oil diet on fatty acid composition of phospholipids of brain membranes and on kinetic properties of Na+,K(+)-ATPase isoenzymes of weaned and adult rats. J Neurochem (1994) 0.79
Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. Eur J Clin Pharmacol (1989) 0.79
Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments. Toxicology (1991) 0.79
Toxicokinetics of paraquat through the heart-lung block. Six cases of acute human poisoning. J Toxicol Clin Toxicol (1988) 0.79
Age-induced cognitive alterations in OF1 mice. Physiol Behav (1999) 0.79
Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol (1996) 0.79
Human monoclonal anti-D with a normal half-life. Transfusion (1993) 0.79
Comparison of plasma and follicular fluid hormone profiles following stimulation with HMG, with or without LHRH agonists, for in-vitro fertilization. Hum Reprod (1991) 0.79
Association constants of monoclonal antibodies for hapten: heterogeneity of frequency distribution and possible relationship with hapten molecular weight. J Immunol Methods (1994) 0.79
Training in basic microsurgical techniques without experiments involving animals. Arch Orthop Trauma Surg (1992) 0.79
Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine. Drug Metab Dispos (1994) 0.79
Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol (1997) 0.79
Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol Sci (2001) 0.79
Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis. Life Sci (1994) 0.79
Simultaneous microdialysis in brain and blood of the mouse: extracellular and intracellular brain colchicine disposition. Brain Res (1998) 0.79
[Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey]. Presse Med (2003) 0.79
Partial splenic artery embolization for thrombocytopenia and uncontrolled massive ascites after liver transplantation. Transplant Proc (2012) 0.79
In Rhizobium leguminosarum, NodD represses its own transcription by competing with RNA polymerase for binding sites. Nucleic Acids Res (2000) 0.79